Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NorthStar Secures Ra-226 Supply with QSA Global | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NorthStar Secures Ra-226 Supply with QSA Global

Strategic partnership aims to strengthen Ac-225 production and improve radiopharmaceutical supply reliability.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

QSA Global Inc., a supplier of specialized radioactive source manufacturing and medical radiochemical services, and NorthStar Medical Radioisotopes, LLC, a radiopharmaceutical company, have entered a multi-year strategic services agreement designed to solidify the supply chain for radium-226 (Ra-226) targets, the starting material for Actinium-225 (Ac-225) production.

The partnership combines QSA Global’s experience in high-activity source handling, industrial regulatory compliance, and logistics with NorthStar’s unique approach to commercial-scale radiopharmaceutical production. It features a multi-year purification campaign where QSA Global will process legacy Ra-226 on behalf of NorthStar, transforming the material into high-purity precursors that will directly feed continuous target capsule manufacturing. Following irradiation and processing by NorthStar to produce n.c.a. Ac-225, the recovered radium will be returned to QSA Global for recycling into new targets—establishing a highly efficient, closed-loop supply chain.

“This multi-year agreement with QSA Global strengthens our supply chain with a reliable, high-quality supply of Ra-226 targets critical to our n.c.a. Ac-225 production capabilities,” said Dr. Frank Scholz, President & CEO of NorthStar. “By ensuring consistent access to these vital starting materials, we can confidently meet growing demand within the industry.”

“By managing the complex, highly regulated lifecycle of radium-226, QSA Global enables partners like NorthStar to focus their resources entirely on commercial Actinium-225 production,” said Joe Lapinskas, Innovation Director at QSA Global, Inc. “We are proud to leverage our decades of high-activity radioactive materials expertise to help secure this critical supply chain and support NorthStar’s mission of delivering life-saving TATs to patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics